Innovation, while universally acknowledged as a driving force behind medical progress, poses unique challenges when applied to oncology. The complex biology of cancers, the diversity of patient responses, and the high stakes involved in drug development and approval processes make defining and evaluating innovation particularly delicate. The study highlights that despite the frequent use of “innovation” in healthcare narratives, consensus on its precise meaning and measurement remains elusive. This ambiguity influences clinical decision-making and the regulatory frameworks governing new therapies.

The researchers conducted an online, anonymous survey targeting a diverse group of French oncology professionals and members of the French Health Technology Assessment (HTA) agency. This approach allowed a multifaceted exploration of attitudes towards innovation, encapsulating both those who deliver care and those responsible for drug assessment and approval. By employing sophisticated statistical techniques such as principal component analysis and cluster analysis, the study unraveled nuanced patterns in respondents’ perceptions.

Among 114 surveyed professionals, two divergent groups emerged clearly: clinicians engaged directly with patient care and health authority representatives overseeing the rigorous evaluation processes. The clinicians tended to favor expedited and simplified evaluation pathways for innovative drugs, driven perhaps by the urgent needs of patients facing life-threatening conditions. Conversely, health authority members emphasized the indispensability of standardized, evidence-based evaluation frameworks to safeguard public health and ensure therapeutic efficacy and safety.

This dichotomy underscores a fundamental tension in oncology innovation: the urgent demand for new therapies against the necessity for robust evidence to justify their use. The study uncovered a third, smaller group of respondents expressing relative indifference toward the evaluation process, suggesting a complex spectrum of engagement levels within the oncology community. Such variability raises compelling questions about how consensus might be built in defining and assessing innovations.

The notion of innovation in this context is intrinsically tied to concepts of novelty, improvement, and advanced therapeutic benefit. Delivering real-world value to patients involves not only scientific novelty but also demonstrable advances over existing treatments. However, the study points out that defining what qualifies as “benefit” can vary substantially depending on stakeholder perspectives—whether measured by survival rates, quality of life improvements, or cost-effectiveness.

These divergent views also reflect differing tolerances for uncertainty in the evidence supporting new treatments. Clinicians may be more willing to embrace therapies showing promising preliminary data, especially in areas of high unmet need, while regulatory bodies demand higher levels of evidence to prevent premature adoption of ineffective or unsafe options. This fundamental contrast shapes the innovation evaluation landscape, often creating friction between rapid access and rigorous assessment.

Importantly, the research highlights the potential for harmonizing these perspectives. The authors advocate for integrating multiple types of evidence—including clinical trial data, real-world evidence, and patient-reported outcomes—in a unified framework that balances rigor with flexibility. This integrative approach could better capture the multifaceted value of innovations, facilitating shared understanding and decision-making among all stakeholders.

Furthermore, the study stresses the ethical imperative that innovation ultimately serves patient interests. Innovation divorced from patient benefit risks becoming a mere marketing buzzword. True therapeutic progress must prioritize improving survival, reducing toxicity, enhancing quality of life, and making treatments accessible. These patient-centered metrics should underpin innovation assessment and guide resource allocation in oncology care.

The complexity of defining therapeutic innovation also extends into broader societal dimensions. Innovations implicate healthcare costs, reimbursement policies, and health equity. Expedited access to novel therapies may strain healthcare budgets and raise difficult questions about cost-effectiveness. This financial dimension adds another layer of challenge to evaluating innovation’s true impact.

The study’s findings speak to the necessity of transparent communication among clinicians, regulators, patients, and payers. Building a shared language and criteria for innovation can reduce misunderstandings and align expectations. Collaborative frameworks could help reconcile the urgency of clinical needs with the caution of scientific validation.

One notable insight from the research is the heterogeneity within the oncology group itself. Not all clinicians uniformly favored simplified evaluation processes, indicating internal debates about acceptable levels of evidence and risk tolerance. This intra-group diversity suggests ongoing evolution in clinical attitudes towards innovation, influenced by emerging data, practice patterns, and regulatory changes.

Looking ahead, the increasing complexity of oncology therapeutics—ranging from personalized medicine and immunotherapy to gene editing—demands sophisticated, adaptable innovation assessment models. The study’s call for merging diverse evidence types and quantifying their contributions encapsulates this imperative. Future evaluation frameworks must be dynamic, accommodating advances while ensuring patient safety and treatment efficacy.

In sum, therapeutic innovation in oncology represents a multifaceted concept that transcends mere novelty. Its evaluation requires balancing accelerated access with rigorous evidence generation, incorporating varied stakeholder perspectives, and focusing unwaveringly on patient benefit. This pivotal research invites the oncology community and policymakers to engage in a constructive dialogue towards consensus, amplifying the transformative potential of innovation for cancer care worldwide.

As the oncology field surges forward with groundbreaking therapies, the wisdom of philosopher Ludwig Wittgenstein’s admonition—“Whereof one cannot speak, thereof one must be silent”—resonates profoundly here. Defining innovation with precise, shared understanding is essential before it can be meaningfully advanced and implemented. This study serves as a crucial step toward that clarity, paving the way for innovations that truly matter to patients battling cancer.

Subject of Research: Perceptions and evaluation of therapeutic innovation in oncology among healthcare professionals and health authority members in France.

Article Title: Therapeutic innovation in oncology: What do you mean? Whereof one cannot speak, thereof one must be silent, L. Wittgenstein

Article References:
Chevret, S., Troussard, X., Masia, C. et al. Therapeutic innovation in oncology: What do you mean? Whereof one cannot speak, thereof one must be silent, L. Wittgenstein. BMC Cancer 25, 1629 (2025). https://doi.org/10.1186/s12885-025-14922-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14922-2

This election marks a pivotal moment for Dr. Sekeres, recognizing his extensive contributions to hematology, particularly in the study and treatment of myelodysplastic syndromes and acute myeloid leukemia (AML) among older adults. His role at Sylvester involves directing an internationally acclaimed program that integrates clinical expertise with cutting-edge research in hematologic malignancies, emphasizing therapeutic innovation tailored to geriatric patient populations.

The American Society of Hematology stands at the forefront of scientific rigor and clinical excellence, advocating vigorously for patients affected by blood disorders. Dr. Sekeres expressed profound honor at joining the executive leadership, highlighting the society’s commitment to advancing the field through robust scientific inquiry, development of clinical guidelines, and education. His impending responsibilities will involve steering ASH’s strategic initiatives during a critical juncture where blood disease research is rapidly evolving.

Since joining ASH in 2002, Dr. Sekeres has been deeply involved in various leadership roles, cultivating comprehensive treatment guidelines targeted at older adults with AML, a demographic often underserved in clinical research. His chairmanship of the Older Adults with AML Treatment Guidelines Panel epitomizes his dedication to integrating evidence-based medicine with compassionate clinical care, addressing the unique challenges posed by age-related physiological changes and comorbidities.

Moreover, his prior leadership includes serving as chair of the Committee on Communications and founding editor-in-chief of ASH Clinical News, a widely read publication that has played an instrumental role in disseminating hematology research and clinical advancements to a broad professional audience. Under his editorial guidance, the publication enhanced its impact, fostering dialogue among clinicians and researchers while promoting accessibility to emerging findings.

The 2025 Executive Committee election also brought in other distinguished leaders, including Alison Loren, M.D., M.S.C.E., chief of the Division of Hematology/Oncology at the University of Pennsylvania, who will serve as vice president, and Adam Cuker, M.D., M.S., a professor of medicine at the same institution, who will serve as councillor. These appointments underscore a trend of fostering interdisciplinary collaboration and integrating diverse academic perspectives to propel hematology forward.

Dr. Belinda Avalos, the 2025 ASH President, emphasized the significance of this leadership team amid an era characterized by both remarkable scientific discoveries and challenges threatening the integrity of the biomedical research ecosystem. She acknowledged that Drs. Loren, Cuker, and Sekeres bring unparalleled expertise essential for navigating the complex landscape of basic science advancements and clinical translation, especially as precision medicine and immunotherapy continue reshaping cancer treatment paradigms.

The Sylvester Comprehensive Cancer Center, home to Dr. Sekeres’s research, is noted for its pioneering work in translational oncology and hematologic research. The center’s focus on integrating molecular genetics, epigenetics, and immunologic factors has contributed substantially to understanding the pathophysiology of AML and related disorders, facilitating the development of targeted agents and personalized therapeutic approaches.

Dr. Sekeres’s ascent to the ASH Executive Committee represents not only personal recognition but also an acknowledgment of the growing importance of geriatric hematology as a subspecialty. The complex interplay of aging biology, comorbid conditions, and hematopoietic dysfunction demands tailored treatment frameworks, an area where his leadership is poised to influence policy, research priorities, and clinical practice guidelines substantially.

As the field confronts emerging hematologic challenges—such as drug resistance mechanisms, clonal hematopoiesis, and the integration of novel immunotherapies—ASH’s governance, enriched by Dr. Sekeres’s expertise, is positioned to play a decisive role in guiding research funding, educational programs, and advocacy efforts that will ultimately improve patient outcomes worldwide.

For those interested in further developments from Sylvester’s research teams and Dr. Sekeres’s ongoing projects, updates and news are regularly posted on the InventUM blog and Sylvester’s official social media channel on platform X (@SylvesterCancer). These platforms provide insights into innovative therapies, clinical trials, and multidisciplinary collaborations aiming to advance hematologic oncology.

In summary, Dr. Mikkael Sekeres’s election to ASH’s Executive Committee is a testament to his exemplary leadership and scientific achievements in hematology. His tenure promises to strengthen the Society’s mission to improve the lives of patients with blood disorders through science-driven care, policy advocacy, and educational excellence during a transformative era in medical science.

Subject of Research: Hematology, focusing on myelodysplastic syndromes and acute myeloid leukemia in older adults.

Article Title: Dr. Mikkael Sekeres Elected to Executive Committee of the American Society of Hematology

News Publication Date: October 16, 2025

Web References:

• University of Miami Miller School of Medicine: https://umiamihealth.org/locations/sylvester-comprehensive-cancer-center
• ASH Annual Meeting 2025: https://www.hematology.org/meetings/annual-meeting
• InventUM blog: https://news.med.miami.edu/
• Sylvester on X: https://x.com/SylvesterCancer

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Hematology, Oncology, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Older Adults, American Society of Hematology, Clinical Guidelines, Blood Disorders, Translational Research, Cancer Therapy, Precision Medicine, Hematologic Malignancies

At the core of this research lies the convergence of multiple scientific disciplines, melding structural bioinformatics, molecular modeling, and machine learning to create molecules that can recognize and bind cancer-associated proteins with remarkable precision. Traditional cancer treatments often suffer from lack of specificity, resulting in collateral damage to healthy tissues. The innovative strategy outlined by Durojaye and colleagues leverages the computational design of protein and peptide binders, aiming to achieve heightened selectivity and efficacy, thereby minimizing systemic toxicity.

The methodology adopted entails a rigorous in silico screening process. Initially, the team identifies key oncogenic proteins that act as drivers of tumor progression. Using structural data derived from crystallography and cryo-electron microscopy, the molecular surfaces of these proteins are meticulously analyzed to pinpoint binding hotspots—regions amenable to modulation by designed molecules. The intricate nature of protein-protein interactions requiring high specificity necessitates a level of computational sophistication considered state-of-the-art.

Subsequently, Durojaye et al. apply novel algorithms to generate and optimize peptide sequences capable of engrafting onto these hotspots. These sequences undergo iterative refinement cycles wherein binding affinity, stability, and specificity are computationally assessed. This approach circumvents the limitations of random peptide screens and expedites the identification of strong candidate binders. Importantly, the designed molecules are not restricted to natural amino acids; innovative inclusion of noncanonical residues enhances target engagement and resistance to proteolytic degradation.

Beyond design, molecular dynamics simulations play a crucial role in validating the behavior of these binders in a quasi-physiological environment. Such simulations allow researchers to observe conformational flexibility and binding kinetics at an atomic level in silico, providing predictive insights into molecule performance before any wet-lab experiments commence. This computational foresight represents a significant cost and time-saving advantage in drug development pipelines.

One of the most compelling aspects of this research is its adaptability. The computational framework established is highly modular, facilitating its application across diverse cancer types with minimal adjustments. Since many cancers share common aberrant signaling proteins, the platform can be rapidly deployed to generate custom binders targeting pathways unique to individual tumor phenotypes, heralding a new era of precision medicine.

Furthermore, the potential of these custom-designed binders extends beyond therapeutic applications. They can serve as tools for diagnostic imaging, enabling enhanced tumor visualization through conjugation with contrast agents or radionuclides. This dual diagnostic-therapeutic (“theranostic”) capability stands to significantly improve early cancer detection and monitoring, allowing clinicians to tailor treatments dynamically in response to tumor evolution.

The integration of artificial intelligence (AI) into this pipeline cannot be overstated. Machine learning algorithms trained on vast datasets of protein sequences and structures facilitate pattern recognition and predictive modeling, accelerating binder design beyond human capability. AI also aids in identifying unintended off-target interactions, enhancing the safety profile of candidate molecules. This symbiosis between computational power and biological insight exemplifies modern drug discovery paradigms.

Crucially, the researchers underscore the importance of experimental corroboration. Candidate protein and peptide binders are synthesized and subjected to rigorous biochemical assays to assess binding affinity and specificity in vitro. Subsequently, cell-based assays evaluate their capacity to interfere with cancer cell proliferation and survival, providing tangible proof of concept. This seamless integration of in silico and in vitro techniques strengthens the translational potential of their findings.

The study also addresses the challenge of immunogenicity, a common obstacle in deploying novel biologics. By simulating immune recognition patterns, the team designs binders less likely to elicit adverse immune responses, a key consideration for clinical implementation. Customization at the sequence level allows fine-tuning to evade host defenses, enhancing therapeutic durability.

From a computational standpoint, the work by Durojaye et al. represents a paradigm shift. They have developed a scalable, reproducible, and efficient platform for rapid binder design, which could democratize access to bespoke cancer therapeutics. This has profound implications not just for oncology but for infectious disease, autoimmune disorders, and beyond, where precisely tailored protein interactors are invaluable.

As this research advances, challenges remain. Translating computational predictions into safe and effective drugs entails navigating complex biological systems in vivo, overcoming hurdles such as delivery, pharmacokinetics, and tumor microenvironment barriers. However, the modular and flexible nature of the computational designs offers avenues to systematically address these issues through iterative optimization cycles.

In the broader context of cancer therapy, the work signals a critical departure from conventional small-molecule drugs and monoclonal antibodies towards a new generation of synthetic biologics. By exploiting the unique advantages of peptides—such as smaller size, easier synthesis, and tunable properties—the approach bridges the gap between large protein therapeutics and traditional chemotherapeutics.

The implications of this study extend to the pharmaceutical industry and personalized medicine. Custom protein and peptide binders designed computationally hold promise as tailored interventions for patients with rare or drug-resistant cancers, where off-the-shelf treatments fail. This individualized strategy aligns with the ongoing shift toward patient-specific therapeutics driven by genomic and proteomic profiling.

Moreover, the environmental footprint of drug development could be reduced through such computational methods. Designing molecules in silico drastically cuts down costly and resource-intensive laboratory experimentation, promoting greener and faster pathways to market. This sustainable aspect adds another layer of appeal amidst global efforts to reduce biomedical waste.

Looking ahead, collaborations between computational biologists, oncologists, structural biologists, and AI experts will be pivotal in refining these methodologies. The cross-disciplinary nature of such endeavors epitomizes the future of biomedical science, where technology and human ingenuity coalesce to confront the complexity of diseases like cancer.

Ultimately, the study by Durojaye and collaborators exemplifies how computational biology can be harnessed to design tailored therapeutics capable of transforming cancer treatment. By strategically engineering protein and peptide binders that outsmart malignant cells, they illuminate a pathway toward highly selective, effective, and safe cancer therapies with the potential for profound clinical impact.

Subject of Research: Computational design of custom protein and peptide binders for targeted cancer therapy.

Article Title: Computational biology meets oncology: designing custom protein and peptide binders to outsmart cancer.

Article References:
Durojaye, O.A., Uzoeto, H.O., Okoro, N.O. et al. Computational biology meets oncology: designing custom protein and peptide binders to outsmart cancer. Med Oncol 42, 361 (2025). https://doi.org/10.1007/s12032-025-02936-6

Image Credits: AI Generated

Historically, the molecular landscape of cancer has posed enormous challenges, particularly in AML. This aggressive blood cancer exhibits a complex network of pathways essential not only to malignant cells but also to normal hematopoietic stem cells, thus creating a precarious therapeutic balance. Conventional drugs, albeit somewhat effective, often falter due to their inability to distinguish thoroughly between malignant and normal cells, resulting in substantial toxicity and poor patient tolerance. This scientific impasse has sustained an urgent demand for selective molecular targets—biomarkers that are expressed predominantly or exclusively on cancerous cells.

The Flynn group’s discovery capitalizes on an unusual feature: the ectopic localization of the RNA-binding protein NPM1 to the exterior of AML cells. While NPM1 traditionally functions within the nucleolus as a chaperone for ribosomal biogenesis and genomic stability, its aberrant expression on the cell surface of cancer cells marks a profound departure from its canonical role. Detailed investigations revealed that cell-surface NPM1 is dramatically upregulated in leukemic cells, with expression levels exceeding those found on healthy blood stem cells by over 100-fold. This significant differential creates a therapeutically exploitable target that, until now, remained concealed within the interior of the cell.

The team elucidated the mechanistic underpinnings of this phenomenon in the context of glycoRNAs—an emerging class of glycoconjugated RNA molecules residing on the cell exterior, which form organized clusters with RNA-binding proteins including NPM1. Prior foundational work has characterized these glycoRNA-protein complexes as novel signaling platforms modulating cellular communication with the microenvironment. This groundbreaking concept redefines the understanding of cell-surface biology, highlighting an uncharted molecular landscape ripe for targeted intervention.

Leveraging this insight, Flynn and colleagues engineered monoclonal antibodies specifically directed against NPM1 presented on the surface of AML cells. These antibodies demonstrated potent anti-leukemic efficacy across multiple preclinical in vivo models, selectively eliminating malignant cells while sparing normal hematopoietic populations. Such specificity is crucial as it addresses one of the most stubborn obstacles in AML treatment—the preservation of healthy bone marrow function during therapy. Notably, the antibodies also effectively targeted leukemic stem cells, the elusive subpopulation responsible for disease initiation, persistence, and relapse.

The impact of targeting leukemic stem cells cannot be overstated. These cells exhibit remarkable resistance to conventional chemotherapies and are often responsible for the clinical recurrence of AML. By attacking these cells head-on through a uniquely surfaced antigen like NPM1, the therapeutic paradigm shifts from merely controlling disease to potentially achieving durable remission or cure. In murine models, this strategy extended survival and markedly reduced disease burden, with no observed off-target toxicity, emphasizing the treatment’s clinical promise.

Beyond leukemia, the research explored the broader oncological relevance of cell-surface NPM1. Screening an extensive panel of 47 human and murine solid tumor models unveiled variable but significant expression of cell-surface NPM1 across many tumor types, including prostate and colorectal carcinomas. These findings suggest a wider applicability of NPM1-targeting antibodies, potentially expanding immunotherapy’s arsenal against notoriously treatment-resistant solid tumors.

The identification of NPM1 as a cell-surface antigen in solid tumors is particularly compelling given the historical difficulty of finding cancer-selective surface markers for these malignancies. Cancers like colorectal carcinoma have long evaded effective immune targeting due to the scarcity of unique markers distinguishable from normal tissue. The cell-surface presentation of NPM1 thus represents a potential ‘molecular handle’ for immune system engagement, a prospect that could reinvigorate therapeutic strategies for multiple cancers.

Crucially, the research underscores the newly appreciated biology of glycoRNAs and RNA-binding proteins as a rich source of tumor-associated antigens. The clustering of these molecules on the cell surface appears not to be a random occurrence but an orchestrated phenomenon potentially advantageous to tumor survival and immune evasion. The team’s future investigations aim to decode the biological imperatives underpinning the externalization of NPM1 and to identify additional molecular candidates within these clusters that could serve as targets or biomarkers.

The discovery that malignant cells co-opt an RNA-binding protein, traditionally intracellular, and mobilize it to the cell membrane hints at a novel tumor strategy that may confer advantages such as altered signaling, adhesion, or immune modulation. Understanding these dynamics will be critical to refining antibody-based therapeutics and possibly integrating them with other modalities, including cellular therapies and immune checkpoint inhibitors.

To translate these foundational findings into clinical impact, Boston Children’s Hospital has already pursued intellectual property protections domestically and internationally. This strategic move paves the way for the development of antibody therapies targeting NPM1, with the potential to enter early-phase clinical trials and ultimately offer new hope to patients with aggressive hematologic and solid malignancies.

The collaboration among interdisciplinary teams spanning molecular biology, oncology, immunotherapy, and structural biochemistry highlights the power of cross-sector partnerships in unearthing novel therapeutic targets. The convergence of expertise in glycoRNA biology, stem cell research, and antibody engineering illustrates a modern scientific approach to solving intractable problems in medicine.

In summary, Dr. Ryan Flynn’s team has illuminated a captivating facet of cancer biology—the aberrant cell-surface expression of an RNA-binding protein—and harnessed it into an actionable therapeutic target. By shifting the paradigm toward precision targeting of cancer stem cells with minimal collateral damage, their work charts a course for next-generation cancer therapies. As future studies delve deeper into the mechanisms and clinical translation, this discovery holds transformative potential for millions battling AML and other formidable cancers, marking a true milestone in the quest for safer, more effective treatments.

Subject of Research: Treatment of acute myeloid leukemia and solid tumors through targeting cell-surface RNA-binding proteins, specifically NPM1.

Article Title: Treatment of acute myeloid leukemia models by targeting a cell-surface RNA-binding protein

News Publication Date: 23-Apr-2025

Web References:
DOI: 10.1038/s41587-025-02648-2
Flynn Lab at Boston Children’s Hospital
Cambridge Stem Cell Institute

Keywords:
Cancer stem cells, RNA binding proteins, Myeloid leukemia, Gene targeting, Molecular targets, Stem cell therapy, Antibody therapy, Monoclonal antibodies, Cell surface receptors